Case-Control Surveillance Study (CCSS)
- Web site: http://www.bu.edu/slone/research/studies/ccs/
- This database includes cancer outcomes.
- This database is not linked to a cancer registry.
The CCSS systematically evaluates the relationship of medications to the incidence of certain illnesses and screens for unsuspected drug/disease associations. Since 1983, the main focus of the study has been on various cancers. Patients from a network of hospitals in Philadelphia who reside in specified ZIP Code areas and have a new (within 1 year) diagnosis of interest (e.g., breast cancer), are identified by nurse interviewers assigned to the hospitals and asked to participate. Non-cancer patients are similarly interviewed in order to amass a pool of potential controls. The data collected include demographic information, lifestyle habits (e.g., smoking, exercise, alcohol use), past and present illnesses, and a lifetime medication history elicited by asking for drug use for over 40 indications. Discharge summaries and pathology reports are reviewed to verify diagnoses, classify, and stage all cancer diagnoses. To date, over 80,000 patients have been interviewed, including over 25,000 with incident cancer.
Rosenberg L, Shapiro S, Kaufman DW, Slone D, Miettinen OS, Stolley PD. Patterns and determinants of conjugated estrogen use. Am J Epidemiol. 1979 Jun;109(6):676-86.
Coogan PF. Review of the epidemiological literature on antidepressant use and breast cancer risk. Expert Rev Neurother. 2006 Sep;6(9):1363-74.
Rosenberg L, Palmer JR, Wise LA, Adams-Campbell LL. A prospective study of female hormone use and breast cancer among black women. Arch Intern Med. 2006 Apr 10;166(7):760-5.
Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Shapiro S. Statin use and the risk of breast and prostate cancer. Epidemiology. 2002 May;13(3):262-7.
Kelly JP, Rosenberg L, Palmer JR, Rao RS, Strom BL, Stolley PD, Zauber AG, Shapiro S. Risk of breast cancer according to use of antidepressants, phenothiazines, and antihistamines. Am J Epidemiol. 1999 Oct 15;150(8):861-8.
Coogan PF, Rao SR, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD, Shapiro S. The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer. Prev Med. 1999 Aug;29(2):72-6.
Zhang Y, Coogan PF, Palmer JR, Strom BL, Rosenberg L. Use of nonsteroidal antiinflammatory drugs and risk of breast cancer: the Case-Control Surveillance Study revisited. Am J Epidemiol. 2005 Jul 15;162(2):165-70.
Blackman JA, Coogan PF, Rosenberg L, Strom BL, Zauber AG, Palmer JR, Langenberg P, Shapiro S. Estrogen replacement therapy and risk of lung cancer by cell type. Pharmacoepidemiol Drug Saf. 2002;11:561-567.
Coogan PF, Palmer JR, Strom BL, Rosenberg L. Use of selective serotonin reuptake inhibitors and the risk of breast cancer. Am J Epidemiol. 2005 Nov 1;162(9):835-8. Epub 2005 Sep 21.
Coogan PF, Rosenberg L, Palmer JR, Strom BL, Stolley PD, Zauber AG, Shapiro S. Risk of ovarian cancer according to use of antidepressants, phenothiazines, and benzodiazepines (United States). Cancer Causes Control. 2000 Oct;11(9):839-45.
Coogan PF, Rosenberg L, Louik C, Zauber AG, Stolley PD, Strom BL, Shapiro S. NSAIDs and risk of colorectal cancer according to presence or absence of family history of the disease. Cancer Causes Control. 2000 Mar;11(3):249-55.